CN109641034B - 聚乙二醇化的猪干扰素及其使用方法 - Google Patents

聚乙二醇化的猪干扰素及其使用方法 Download PDF

Info

Publication number
CN109641034B
CN109641034B CN201780051072.0A CN201780051072A CN109641034B CN 109641034 B CN109641034 B CN 109641034B CN 201780051072 A CN201780051072 A CN 201780051072A CN 109641034 B CN109641034 B CN 109641034B
Authority
CN
China
Prior art keywords
alpha
pinf
variant
variants
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780051072.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN109641034A (zh
Inventor
P.C.肯宁
N.克努森
L.斯基摩尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Ambrx Inc
Original Assignee
Eli Lilly and Co
Ambrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co, Ambrx Inc filed Critical Eli Lilly and Co
Priority to CN202310995289.4A priority Critical patent/CN117024562A/zh
Publication of CN109641034A publication Critical patent/CN109641034A/zh
Application granted granted Critical
Publication of CN109641034B publication Critical patent/CN109641034B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201780051072.0A 2016-06-20 2017-06-16 聚乙二醇化的猪干扰素及其使用方法 Active CN109641034B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310995289.4A CN117024562A (zh) 2016-06-20 2017-06-16 聚乙二醇化的猪干扰素及其使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662352163P 2016-06-20 2016-06-20
US62/352163 2016-06-20
PCT/US2017/037964 WO2017222940A1 (en) 2016-06-20 2017-06-16 Pegylated porcine interferon and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310995289.4A Division CN117024562A (zh) 2016-06-20 2017-06-16 聚乙二醇化的猪干扰素及其使用方法

Publications (2)

Publication Number Publication Date
CN109641034A CN109641034A (zh) 2019-04-16
CN109641034B true CN109641034B (zh) 2023-08-15

Family

ID=59258379

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780051072.0A Active CN109641034B (zh) 2016-06-20 2017-06-16 聚乙二醇化的猪干扰素及其使用方法
CN202310995289.4A Pending CN117024562A (zh) 2016-06-20 2017-06-16 聚乙二醇化的猪干扰素及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310995289.4A Pending CN117024562A (zh) 2016-06-20 2017-06-16 聚乙二醇化的猪干扰素及其使用方法

Country Status (17)

Country Link
US (2) US10960080B2 (cg-RX-API-DMAC7.html)
EP (1) EP3471755B1 (cg-RX-API-DMAC7.html)
JP (2) JP7093311B2 (cg-RX-API-DMAC7.html)
KR (2) KR102518451B1 (cg-RX-API-DMAC7.html)
CN (2) CN109641034B (cg-RX-API-DMAC7.html)
AU (2) AU2017280958A1 (cg-RX-API-DMAC7.html)
CA (1) CA3028683A1 (cg-RX-API-DMAC7.html)
CL (1) CL2018003697A1 (cg-RX-API-DMAC7.html)
DK (1) DK3471755T3 (cg-RX-API-DMAC7.html)
EA (1) EA036509B1 (cg-RX-API-DMAC7.html)
ES (1) ES2793773T3 (cg-RX-API-DMAC7.html)
MX (1) MX391970B (cg-RX-API-DMAC7.html)
NZ (1) NZ749962A (cg-RX-API-DMAC7.html)
PL (1) PL3471755T3 (cg-RX-API-DMAC7.html)
PT (1) PT3471755T (cg-RX-API-DMAC7.html)
WO (1) WO2017222940A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201808352B (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
MD3377488T2 (ro) 2015-11-19 2023-02-28 Incyte Corp Compuși heterociclici ca imunomodulatori
ES2916874T3 (es) 2015-12-17 2022-07-06 Incyte Corp Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1
CA3009474A1 (en) 2015-12-22 2017-06-29 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2906460T3 (es) 2016-05-06 2022-04-18 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
EP3464279B1 (en) 2016-05-26 2021-11-24 Incyte Corporation Heterocyclic compounds as immunomodulators
SG11201811414TA (en) 2016-06-20 2019-01-30 Incyte Corp Heterocyclic compounds as immunomodulators
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
US10308644B2 (en) 2016-12-22 2019-06-04 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
WO2018119286A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
EP4223369A1 (en) 2016-12-22 2023-08-09 Incyte Corporation Immunomodulator compounds and methods of use
SMT202300065T1 (it) 2018-03-30 2023-05-12 Incyte Corp Composti eterociclici come immunomodulatori
CN112752756B (zh) 2018-05-11 2024-06-25 因赛特公司 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物
TW202115059A (zh) 2019-08-09 2021-04-16 美商英塞特公司 Pd—1/pd—l1抑制劑之鹽
CN110343164A (zh) * 2019-08-22 2019-10-18 安阳工学院 一种高活性7位点突变的猪干扰素α突变体及其制备方法和应用
JP7559059B2 (ja) 2019-09-30 2024-10-01 インサイト・コーポレイション 免疫調節剤としてのピリド[3,2-d]ピリミジン化合物
EP4058461A1 (en) 2019-11-11 2022-09-21 Incyte Corporation Salts and crystalline forms of a pd-1/pd-l1 inhibitor
IL302590A (en) 2020-11-06 2023-07-01 Incyte Corp Process for preparing PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
CN113845599B (zh) * 2021-11-01 2023-09-19 长春萤火虫生物科技有限公司 一种重组猪干扰素融合蛋白及其应用
WO2024241086A1 (en) 2023-05-24 2024-11-28 Ambrx, Inc. Pegylated bovine interferon lambda and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104262480A (zh) * 2014-09-28 2015-01-07 重庆理工大学 重组猪长效-α干扰素的构建和修饰方法及其冻干注射剂的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858409B1 (en) * 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
HUT75533A (en) * 1993-11-10 1997-05-28 Schering Corp Improved interferon polymer conjugates
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US20050226845A1 (en) * 2004-03-10 2005-10-13 Chih-Ping Liu Method of treatment using interferon-tau
JP2006213597A (ja) 2000-07-19 2006-08-17 Pepgen Corp インターフェロン−タウを用いるc型肝炎ウイルスの処置のための組成物およびモニタリングの方法
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
KR20080026135A (ko) 2005-06-03 2008-03-24 암브룩스, 인코포레이티드 개선된 인간 인터페론 분자 및 이의 용도
US7695710B2 (en) * 2005-06-20 2010-04-13 Pepgen Corporation Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
CN101883784B (zh) 2007-10-01 2014-10-15 药华医药股份有限公司 N-端修饰的干扰素-α
EP2318029B1 (en) 2008-07-23 2017-11-01 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104262480A (zh) * 2014-09-28 2015-01-07 重庆理工大学 重组猪长效-α干扰素的构建和修饰方法及其冻干注射剂的制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Molecular cloning and sequencing of a genen encoding biologically active porcine alpha-interferon;lefever f等;《j interferon res》;19860801;第6卷(第4期);349-360 *

Also Published As

Publication number Publication date
JP2022137063A (ja) 2022-09-21
PT3471755T (pt) 2020-05-22
US20190192673A1 (en) 2019-06-27
AU2021229132B2 (en) 2023-04-06
EP3471755B1 (en) 2020-04-22
JP2019519553A (ja) 2019-07-11
CA3028683A1 (en) 2017-12-28
JP7441892B2 (ja) 2024-03-01
CL2018003697A1 (es) 2019-05-10
WO2017222940A1 (en) 2017-12-28
EP3471755A1 (en) 2019-04-24
AU2017280958A1 (en) 2018-12-20
PL3471755T3 (pl) 2020-10-19
KR20190039889A (ko) 2019-04-16
MX2018016295A (es) 2019-09-16
ES2793773T3 (es) 2020-11-16
AU2021229132A1 (en) 2021-09-30
CN109641034A (zh) 2019-04-16
KR102409470B1 (ko) 2022-06-16
JP7093311B2 (ja) 2022-06-29
KR102518451B1 (ko) 2023-04-04
NZ749962A (en) 2020-06-26
US10960080B2 (en) 2021-03-30
KR20220086700A (ko) 2022-06-23
CN117024562A (zh) 2023-11-10
ZA201808352B (en) 2020-08-26
MX391970B (es) 2025-03-21
BR112018076437A2 (pt) 2019-10-01
DK3471755T3 (da) 2020-05-18
US12653897B2 (en) 2026-06-16
EA201892671A1 (ru) 2019-05-31
EA036509B1 (ru) 2020-11-18
US20210177980A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
JP7441892B2 (ja) ペグ化ブタインターフェロンおよびその使用方法
KR20090089316A (ko) Peg 변형된 엑센딘 또는 엑센딘 유사체 및 조성물 및 이의 용도
JP2019519553A5 (cg-RX-API-DMAC7.html)
JP2012526789A (ja) インターフェロンをpegで標識する方法
US20230399364A1 (en) Immunogenic Coronavirus Fusion Proteins and Related Methods
US20110281806A1 (en) Peptides for preventing or treating liver damage
CN113425832A (zh) 干扰素λ在新型冠状病毒(2019-nCoV)感染治疗中的应用
CN101671390B (zh) 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途
WO2005105151A1 (en) Pegylated thymosin 1 derivatives
CN103096916B (zh) 用于牛粒细胞集落刺激因子及其变体的制剂
EP4267166A1 (en) Blockade of sars-cov-2 infection using hydrocarbon stapled peptides
WO2024241086A1 (en) Pegylated bovine interferon lambda and methods of use thereof
CN116964104A (zh) 免疫原性冠状病毒融合蛋白及相关方法
WO2024059149A2 (en) Immunogenic coronavirus fusion proteins and related methods
EA052740B1 (ru) Иммуногенные слитые белки коронавируса и связанные с ними способы
HK40108760A (en) Therapeutic derivatives of interleukin-22
CN120965829A (zh) 广谱抗冠状病毒脂肽
CA3174685A1 (en) Immunogenic coronavirus fusion proteins and related methods
Chan Development of recombinant human augmenter of liver regeneration (ALR) for treatment of liver diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant